Compare Viatris Inc (VTRS) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Xcel Energy Inc — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Xcel Energy Inc trades at $78.62 (market cap $49.11B). The key difference: Xcel Energy Inc is far larger — about 2.5× Viatris Inc's market cap, and Xcel Energy Inc pays the higher dividend (3.01%). Which is the better fit depends on your goals.
| VTRS | XEL | |
|---|---|---|
Market Cap | $19.79B | $49.11B |
Sector | Health | Utilities |
52-Week High | $17.39 | $83.91 |
52-Week Low | $8.74 | $71.14 |
Enterprise Value | $32.00B | $86.55B |
Dividend Yield | 2.83% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
XEL trades at $78.72, down 0.06% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $14.67B in 2025, with a net income margin of 14.14%. Analyst consensus is bullish with a $94.50 price target, and the company maintains a steady dividend, with a recent payout declared for July 2026.
The outlook for XEL is supported by strong analyst buy ratings and a significant capital expenditure plan targeting growth, but risks include regulatory pushback and high debt levels. The stock's current valuation near historical highs requires monitoring of earnings delivery against expectations, particularly the upcoming Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
